FDA calendar · October 2024 · built from SEC filings

PDUFA dates October 2024: FDA calendar and catalysts.

Updated Snapshot 20261116T112050ZBuilt

1 PDUFA date fell in October 2024: TLX101 (Oct 2024). The FDA calendar also recorded 60 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in October 2024

1 PDUFA target action date in October 2024, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
Oct 2024Telix Pharmaceuticals LtdTLXTLX101SEC Form 10-K, filed 2026-02-20

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

October 2024: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Oct 2024Month disclosed—ABEONDA/BLA submission—CompletedSEC 8-K Exhibit 99.1
Oct 2024Month disclosedreproxalapALDXNDA/BLA submissionsigns and symptoms of dry eye disease in October 2024CompletedSEC Form 8-K
Oct 2024Month disclosedreproxalapALDXComplete Response Letter—CRL issuedSEC Form 10-Q
Oct 2024Month disclosedWEZLANA® (ustekinumab)ALVOFDA approval—ApprovedSEC 8-K Exhibit 99.1
Oct 2024Month disclosedAmeluzBFRILabel expansion—Approvedsec_s1
Oct 2024Month disclosedTranslarna™ (ataluren)EWTXNDA/BLA submission—CompletedSEC Form 10-K
Oct 2024Month disclosedJAKAFI (ruxolitinib)INCYNDA/BLA submission—CompletedSEC 8-K Exhibit 99.1
Oct 2024Month disclosedLNZ100LENZNDA/BLA acceptedpresbyopia, a conditionCompletedSEC 8-K Exhibit 99.1
Oct 2024Month disclosedIBTROZI (taletrectinib)NUVBNDA/BLA submissionwith advanced ROS1+ NSCLCCompletedSEC Form 10-Q
Oct 2024Month disclosedTLX101TLXNDA/BLA accepted—CompletedSEC 8-K Exhibit 99.1
Oct 2024Month disclosedZUSDURI (mitomycin)URGNNDA/BLA accepted—CompletedSEC Form 10-Q
Oct 2024Month disclosedLuaZLABFDA approvalmetastatic NSCLC in October 2024ApprovedSEC 8-K Exhibit 99.1
October 3, 2024Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
October 4, 2024Pyridostigmine Bromide (pyridostigmine bromide)AMRXFDA approval—ApprovedopenFDA Drugs@FDA
October 4, 2024Ameluz (aminolevulinic acid hydrochloride)BFRILabel expansion—ApprovedopenFDA Drugs@FDA
October 9, 2024AMVUTTRA® (vutrisiran)ALNYNDA/BLA submission—CompletedSEC Form 10-K
October 11, 2024Kombiglyze Xr (metformin hydrochloride; saxagliptin hydrochloride)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
October 11, 2024Onglyza (saxagliptin hydrochloride)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
October 11, 2024Hympavzi (marstacimab-hncq)PFEFDA approvalTo prevent or reduce bleeding episodes related to hemophilia A or BPress ReleaseApprovedFDA Novel Drug Approvals
October 15, 2024Fragmin (dalteparin sodium)PFELabel expansion—ApprovedopenFDA Drugs@FDA
October 16, 2024Vyalev (foscarbidopa; foslevodopa)ABBVFDA approval—ApprovedopenFDA Drugs@FDA
October 16, 2024Lumryz (sodium oxybate)ALKSLabel expansion—ApprovedopenFDA Drugs@FDA
October 18, 2024Botox Cosmetic (onabotulinumtoxina)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
October 18, 2024Zepbound (tirzepatide)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
October 22, 2024SELARSDITEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
October 25, 2024Sarclisa (isatuximab-irfc)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
October 29, 2024Scemblix (asciminib)NVSLabel expansion—ApprovedopenFDA Drugs@FDA

October 2024: dated readouts

DateDrugCompanyEventIndicationStatusSource
Oct 2024Month disclosedAMX0035AMLXTopline readout—Positivesec_424b
Oct 2024Month disclosedALTO-100ANROTopline readout—NegativeSEC Form 10-Q
Oct 2024Month disclosed—AQSTTopline readout—Met primary endpointSEC Form 10-Q
Oct 2024Month disclosedATH434ATHEInterim readout—PositiveSEC 8-K Exhibit 99.1
Oct 2024Month disclosed—GYRETopline readout—Met primary endpointSEC 8-K Exhibit 99.1
Oct 2024Month disclosed—GYRETopline readout—Met primary endpointSEC 8-K Exhibit 99.1
Oct 2024Month disclosed—JAZZTopline readout—Met primary endpointSEC Form 10-Q
Oct 2024Month disclosedTecentriq® (atezolizumab)JAZZTopline readout—Met primary endpointSEC Form 10-Q
Oct 2024Month disclosedZepzelca (lurbinectedin)JAZZTopline readout—Met primary endpointSEC Form 10-Q
Oct 2024Month discloseddabogratinib (TYRA-300)TYRAInterim readout—PositiveSEC Form 10-K
Oct 2024Month disclosed—VRCAInterim readout—PositiveSEC 8-K Exhibit 99.1
Oct 2024Month disclosed—ZLABTopline readout—PositiveSEC 8-K Exhibit 99.1
October 7, 2024ISEMBYLD (apitegromab)SRRKTopline readoutnon-ambulatory Type 2 and Type 3 SMAPositivesec_424b
October 22, 2024—IMUXInterim readout—Positivesec_424b
October 22, 2024vidofludimusIMUXInterim readout—Positivesec_424b
October 22, 2024—IMUXInterim readout—PositiveSEC Form 10-K
October 27, 2024JX07001LENZTopline readoutpresbyopia in ChinaPositiveSEC Form 10-Q
October 29, 2024SPR720SPROInterim readoutNTM-PD not meeting its primary endpointMet primary endpointSEC Form 10-Q

October 2024: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Oct 2024Month disclosedZUSDURI (mitomycin)URGNTrial start—CompletedSEC Form 10-Q
Oct 2024Month disclosedobefazimod (ABX464)ABVXTrial startCrohn's diseaseCompletedsec_424b
Oct 2024Month disclosedCORE-008CGONTrial start—CompletedSEC Form 10-Q
Oct 2024Month disclosedVIRO-25GNLXTrial startrecurrent NSCLCCompletedSEC Form 10-Q
Oct 2024Month disclosedRLYB212RLYBTrial start—CompletedSEC 8-K Exhibit 99.1
Oct 2024Month disclosedVancomycin Hydrochloride (vancomycin)RXRXTrial starthigh-risk of CDICompletedSEC Form 10-K
October 6, 2024risvodetinib (IkT-148009)IKTTrial start—CompletedSEC Form 10-Q
October 29, 2024Joenja® (leniolisib)PHARTrial start—CompletedSEC Form 8-K
Oct 2024Month disclosedFHD-909FHTXTrial start—CompletedSEC 8-K Exhibit 99.1
Oct 2024Month disclosedIDE275IDYATrial startMSI-High tumors pursuantCompletedSEC Form 10-K
Oct 2024Month disclosedKT-621KYMRTrial start—CompletedSEC 8-K Exhibit 99.1
Oct 2024Month disclosedONUREG (azacitidine)PMVPTrial start—CompletedSEC Form 10-K
Oct 2024Month disclosedsclerosis (AMT-162)QURETrial start—CompletedSEC Form 10-K
October 29, 2024FSD-201QNTMTrial start—CompletedSEC 8-K Exhibit 99.1
Oct 2024Month disclosedINT230INTSTrial start—CompletedSEC 8-K Exhibit 99.1

Guided to a window that includes October 2024

Milestones the sponsor disclosed to a quarter, tightest windows first.

DateDrugCompanyEventIndicationStatusSource
Q4 2024Quarter disclosed—ASNDTopline readout—ScheduledSEC Form 8-K
Q4 2024Quarter disclosed—ASNDTopline readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedfirmonertinib (AST2818)AVBPTrial startclassical EGFR mutationsScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedAXS-07AXSMTopline readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedAUVELITY (dextromethorphan-bupropion)AXSMTopline readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedreboxetine (AXS-12)AXSMTopline readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedAXS-07AXSMPDUFA date—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedVYGLXIA (troriluzole)BHVNInterim readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedBHV-1600BHVNTrial start—ScheduledSEC Form 10-Q
Q4 2024Quarter disclosedTRAP (nephropathy)BHVNTrial start—ScheduledSEC Form 10-Q
Q4 2024Quarter disclosedVYGLXIA (troriluzole)BHVNTopline readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedBHV-1310BHVNTrial start—ScheduledSEC Form 10-Q
Q4 2024Quarter disclosedaglatimagene besadenovec (CAN-2409)CADLTopline readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedGS-0321CGENTrial start—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosed—FBIOTopline readout—ScheduledSEC Form 10-Q
Q4 2024Quarter disclosed—GALTTopline readout—ScheduledSEC Form 10-Q
Q4 2024Quarter disclosedmebufotenin (GH001)GHRSTopline readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosed—GOVXInterim readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosedVYD2311IVVDInterim readout—ScheduledSEC 8-K Exhibit 99.1
Q4 2024Quarter disclosed—NAMSTopline readout—ScheduledSEC 8-K Exhibit 99.1

4 more in October 2024 are on each drug page and in the calendar API (/api/v1/biotech/calendar?from=2024-10-01&to=2024-10-31).

25 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps October 2024. They are on each drug page and in the calendar API.

Questions

What PDUFA dates are in October 2024?

1 PDUFA date fell in October 2024: TLX101 (Oct 2024). The FDA calendar also recorded 60 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.